# OnCo record nct04256317 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04256317/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04256317", "NCT04256317" ;
  schema:name "A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)"@en ;
  schema:alternateName "AZTOUND"@en ;
  schema:description "A phase 2/3 trial of Azacitidine and Venetoclax in myelodysplastic syndromes / neoplasms, acute myeloid leukaemia and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Taiho Oncology, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04256317/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04256317> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2020-05-21" ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/cmml/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/araris/> .